Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-resistant Depression (TRD) Clear all
Terminated Phase 2 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

NCT05414422
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
PCN-101, Placebo
Drug
Lead sponsor
Perception Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 24, 2026, 12:28 AM EDT
Active, not recruiting Not applicable Interventional

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

NCT05172271
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions
MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation
Device · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
25 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Terminated Not applicable Interventional Results available

Maintenance TMS in Treatment Resistant Depression

NCT06682299
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Transmagnetic Stimulation, Electroconvulsive Therapy
Device
Lead sponsor
Austin Messner
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Active, not recruiting Phase 2 Interventional

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

NCT04433858
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Aripiprazole as Augmentation for TRD

NCT00174876
View directory record Official record
Conditions
Depression
Interventions
Drug Abilify
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Jul 24, 2026, 12:28 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Recruiting Not applicable Interventional

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

NCT04080778
View directory record Official record
Conditions
Bipolar Disorder
Interventions
magnetic seizure therapy (MST), electroconvulsive therapy (ECT)
Device
Lead sponsor
Joao L. DeQuevedo
Other
Eligibility
22 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 24, 2026, 12:28 AM EDT
Recruiting Not applicable Interventional

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

NCT03887715
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Vagus Nerve Stimulation (VNS)
Device
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
6,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
101
States / cities
Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Phase 4 Interventional Results available

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

NCT03149991
View directory record Official record
Conditions
Depression
Interventions
Brexpiprazole, Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jul 24, 2026, 12:28 AM EDT
Withdrawn Phase 2 Interventional

N2O for Acute Suicidality and Depression in the ED

NCT05710887
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Not applicable Interventional Results available

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)

NCT03068715
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC, Open label TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 24, 2026, 12:28 AM EDT
Terminated Early Phase 1 Interventional Results available

Nitrous TRD Bipolar Depression

NCT02757521
View directory record Official record
Conditions
Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder
Interventions
Nitrous Oxide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 24, 2026, 12:28 AM EDT
Recruiting Phase 2 Interventional

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637
View directory record Official record
Conditions
Treatment-resistant Depression (TRD)
Interventions
ALTO-207, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

NCT04663321
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Terminated No phase listed Observational

The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

NCT04753385
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Costa Mesa, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Not applicable Interventional

Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)

NCT00533832
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vagus nerve stimulation (VNS)
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2007 · Synced Jul 24, 2026, 12:28 AM EDT
Not listed Phase 2 Interventional

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

NCT04971291
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
AXS-05, Bupropion SR
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Jul 24, 2026, 12:28 AM EDT
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)

NCT06236711
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
tDCS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429
View directory record Official record
Conditions
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions
SCC DBS
Device
Lead sponsor
Paul Holtzheimer
Other
Eligibility
22 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Jul 24, 2026, 12:28 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 24, 2026, 12:28 AM EDT
Recruiting No phase listed Observational

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

NCT07528014
View directory record Official record
Conditions
Depressed Mood
Interventions
Not listed
Lead sponsor
Salma Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
La Jolla, California • Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Phase 1 Interventional

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

NCT02911597
View directory record Official record
Conditions
Depression
Interventions
Naltrexone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Jul 24, 2026, 12:28 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

NCT01246908
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Placebo, CX157 (TriRima)
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
30
States / cities
Escondido, California • National City, California • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Jul 24, 2026, 12:28 AM EDT